Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SQZ-eAPC-HPV |
Trade Name | |
Synonyms | |
Drug Descriptions |
SQZ-eAPC-HPV are antigen-presenting cells engineered with mRNAs encoding HPV16 E6 and E7 antigens, CD86, and membrane bound IL-2 and IL-12, which may lead to a a cytotoxic T-lymphocyte (CTL)-mediated response against HPV16 E6/E7-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2022;10; NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C190037 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + SQZ-eAPC-HPV | Pembrolizumab SQZ-eAPC-HPV | 0 | 1 |
SQZ-eAPC-HPV | SQZ-eAPC-HPV | 0 | 1 |